Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech
This article was originally published in The Pink Sheet Daily
Executive Summary
The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.
You may also be interested in...
NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients
Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.
NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients
Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.
Lucentis SAILOR Trial Hits Choppy Water
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.